Trial Information

Summary: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer

Status: Recruiting

Protocol Number: BO15943

Sponsor: Hoffman-La Roche Ltd Global Development

Company Division: Pharmaceutical

Official Scientific Title: A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.

Brief Summary: This study will evaluate the long-term safety of treatment with Herceptin in patients with metastatic breast cancer with HER2 overexpression who have completed a prior study with Herceptin. The anticipated time on study treatment is until Herceptin becomes commercially available or until disease progression , and the target sample size is <100 individuals. Target sample size is 23.

Study Phase: IV

Study Design / Study Details:

• Purpose: Treatment
• Allocation: Non-Randomized
• Masking: Open Label
• Control: Uncontrolled
• Assignment: Single Group
• Endpoints: Safety/Efficacy

Study Type:

Condition: Breast Cancer

Intervention Type: Drug

Intervention Name: trastuzumab[Herceptin]

Primary Outcome: 1. Clinical outcome

Key Secondary Outcomes: 1. Safety: Serious adverse events

Inclusion Criteria:

Exclusion Criteria:

Gender: Females

Age Limits: Min: 18 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: June, 1999

Trial Registration Date: 06/24/2005

Date Last Updated: 04/16/2008

Link To Trial Results

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: May 13, 2008 at 1:49:53 PM